InnoCare Announces Approval of Orelabrutinib in Combination with R-CHOP as First-Line Therapy for Mantle Cell Lymphoma in China
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that China National Medical…